Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gp100:209-217 (210M) peptide vaccine
- Development stage
- Unknown
- Lead developer
- University of Illinois Chicago
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
gp100:209-217 (210M) is a synthetic peptide cancer vaccine consisting of amino acid residues 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen, with a methionine substitution at position 210 to increase its binding affinity for the HLA-A2 molecule. This biologic immunotherapy is designed to stimulate the immune system, specifically inducing a cytotoxic T-lymphocyte (CTL) response against melanoma cells that express the gp100 protein. It is typically administered as an emulsion with the adjuvant Montanide ISA-51 (incomplete Freund's adjuvant) and has been extensively evaluated in clinical trials, often in combination with high-dose interleukin-2 (IL-2), for the treatment of HLA-A2.1-positive patients with advanced metastatic melanoma.
- Other names
- gp100 melanoma peptide vaccinegp-100 melanoma peptide vaccinegp 100 melanoma peptide vaccinemutated gp100 melanoma peptidegp100:209-217(210M) peptidegp100:209-217 (210M)-University of Illinois at Chicago-melanoma
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on gp100:209-217 (210M) peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gp100:209-217 (210M) peptide vaccine.